PE-22-28

What it is

PE-22-28 is for the person with a flat, low mood who has tried the usual things and is curious about the newer brain peptides, and who is willing to run a short, careful experiment. In mice it lifts mood-like behavior within days rather than weeks. In people, almost nothing has been measured.

The people who try it are mostly those with low mood, low motivation or a brain-fog slump who have not clicked with conventional options, and who already know Semax and Selank. It is not for anyone in crisis, anyone with bipolar disorder or a psychotic history, or anyone on antidepressants who has not involved their prescriber; there is no data on how it interacts with any of that.

If it works for you, it tends to be fast: people who respond describe a lift in motivation and a quieter, less heavy mood within the first one to two weeks, sometimes within days. Some notice better sleep and sharper recall alongside. If nothing has shifted by week three or four, stop; it is not the kind of peptide that needs months to build. It will not fix a mood driven by sleep debt, alcohol or a situation that needs changing, and it is not a treatment for diagnosed depression.

Start at 100 mcg once a day subQ, move to 200 mcg after the first week, and treat 250 to 300 mcg as the top. Timing is flexible; morning suits most, since a minority feel more alert on it. Keep runs short (a few weeks), log mood daily so you can actually tell, and change nothing else at the same time. Then stop and see whether the change holds before deciding on another run; too little is known to set a fixed cycle. A 5 mg vial reconstituted with 2 ml is 25 doses at 200 mcg, so one vial is a full trial run. The mistake is stacking it with Semax, Selank and a nootropic in week one, then having no idea what did what.

The science is young. PE-22-28 is a short fragment of spadin, a natural brain peptide, and it blocks a potassium channel called TREK-1 that is involved in mood regulation; in mouse tests of depression-like behavior it worked within a few days, where standard antidepressants take weeks, and it appeared to promote new connections in the hippocampus. Human data is a handful of early reports. So: an interesting mechanism, a real animal signal, and essentially nothing proven in people. Not approved anywhere.

If you want something with more track record for low mood and anxiety, Selank has decades of Russian clinical use and is a nasal spray. If motivation and focus are the problem, Semax is the better-known pick. PE-22-28 is the experimental option you try after those, not instead of them.

What people use it for

How it works

Safety, in brief

The full picture — stop signs and who should talk to a doctor first — is on the dosing guide.

Sources

The labels and studies behind this page. Each link opens the original on PubMed, DailyMed or ClinicalTrials.gov.

1. Shortened Spadin Analogs Display Better TREK-1 Inhibition, In Vivo Stability and Antidepressant ActivityDjillani et al., Front Pharmacol 2017 · Study
2. Spadin, a sortilin-derived peptide, targeting rodent TREK-1 channels: a new concept in the antidepressant drug designMazella et al., PLoS Biol 2010 · Study
3. Fighting against depression with TREK-1 blockers: Past and future. A focus on spadinDjillani et al., Pharmacol Ther 2019 · Review